摘要
目的 观察小剂量 (5 0 m g)重组组织型纤溶酶原激活剂 (rt- PA)和尿激酶 (U K)治疗急性心肌梗死(AMI)的疗效及安全性。方法 将 116例 AMI患者随机分为 rt- PA组和 UK组 ,分别应用 rt- PA和 U K溶栓治疗。结果 冠状动脉 (冠脉 )总再通率分别为 rt- PA组 80 .6 5 %和 U K组为 5 1.85 % ;患者在发病后 6小时内治疗 ,冠脉再通率分别为 rt-PA组 91.18%和 UK组 6 7.86 % ,前者明显高于后者 ,两组比较均有显著差异 (P <0 .0 1)。 5周住院病死率 分别为 rt- PA组 6 .5 %和 U K组 11.1%。结论 小剂量 (5 0 m g) rt- PA用于 AMI溶栓治疗的临床疗效明显优于 U K,血管再通率高 ,尤其在发病后 6小时内进行治疗效果更佳 ;rt- PA溶栓并发症少 ,可降低病死率 。
Objective To observe the effectiveness and safety of thromolytic therapy with 50mg of recombinant tissue plasminogen activator (rt PA) a compared with urokinase (UK) for acute myoca rdial infarction (AMI) Methods 116Patients with AMI were randomized to receive 50mg of rt PA (rt PA group) or 1 5 million units of UK(UK group) Results The total reperfusion rate was 80 65% in rt PA group,and 51 85% in UK group When thrombolysis was given in 6 hours from symptom onset,the reperfusion rate was higher in rt PA group than that in UK group (91 18%vs67 86%) There were both sigmificant difference(P<0 01) The mortality during 5 week hlspitalization was 6 5%(rt PA group)vs 11 1%(UK group) ConclusionsThrombolytic with 50mg of rt PA is significantly more efficaceous than that with UK,especially in 6 hours from onset The reperfusion rate is higher,the mortality can be reduced an complications appear to be rate in rt PA group The data indicate that rt PA is effective and safe in thrombolytic therapy for acute myocardial infarction
出处
《医学文选》
2001年第5期594-596,共3页
Anthology of Medicine
关键词
心肌梗死
重组组织型纤溶酶原激活剂
尿激酶
溶栓治疗
myocardial infarction
recombinant tissue plasminogen activator
urokinase
thrombolytic therapy
